Does Highmark Cover Zepbound? Prior Authorization, Costs, and Appeals

Highmark does cover Zepbound for weight loss on its commercial employer plans and ACA marketplace plans, but only with prior authorization, a qualifying BMI, documented lifestyle changes, and proof the medication is working. Medicare plans administered by Highmark generally do not cover it, and Highmark Health Options Medicaid plans classify it as non-preferred, which means you have to try other weight-loss drugs first.¹

Which Highmark Plans Cover Zepbound

Highmark places Zepbound under its anti-obesity drug program for members enrolled in commercial employer-sponsored plans and in individual or small-group Healthcare Reform (ACA) plans.¹ Which formulary governs you depends on plan type, not where you live. Employer plans may fall under the Comprehensive, National Select, or Core formularies; ACA plans use the Essential or Comprehensive Healthcare Reform formularies.²

One format exclusion applies across every Highmark plan: the Zepbound single-dose vials are not billable through insurance. They are available only to self-pay patients with an on-label prescription. The prefilled pens are the covered form.¹

Medicare

Federal law bars Medicare Part D from covering medications prescribed solely for weight loss, and Highmark’s Medicare plans follow that rule.³ A temporary opening arrives July 1, 2026, when CMS launches the Medicare GLP-1 Bridge program. It covers Zepbound KwikPens (not vials or other pens) for Part D beneficiaries who meet BMI and health-condition criteria, with a flat $50 monthly copay that does not count toward the Part D deductible or out-of-pocket maximum. The program runs through December 31, 2027, and uses its own prior authorization separate from any Part D plan.⁴

Highmark Health Options (Medicaid)

Highmark Health Options administers Medicaid managed-care plans in Delaware and West Virginia and does not list Zepbound as a preferred weight-loss agent. The preferred options are phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), and semaglutide (Wegovy). You must try and fail two of those preferred drugs before Zepbound coverage will be considered.⁵

What Prior Authorization Requires

Every Highmark plan that covers Zepbound requires prior authorization. Highmark runs two separate anti-obesity utilization management policies for commercial and ACA members, and the one that applies to your plan sets the bar. The Standard policy (J-1389) has lower entry thresholds. The Enhanced policy (J-1388) is stricter.

Standard Policy

Under the Standard policy, adults 18 and older can be approved if they meet all of the following:⁶

Baseline BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, cardiovascular disease, dyslipidemia, or obstructive sleep apnea.
The prescriber confirms you have actively participated in a reduced-calorie diet and increased physical activity for at least three months before starting the medication, and will continue doing so.
You are not taking any other GLP-1 receptor agonist or GLP-1 combination product.

Standard does not require you to try and fail other weight-loss drugs before Zepbound.⁶

Enhanced Policy

The Enhanced policy sets a materially higher bar:⁷

Baseline BMI must be 40 or higher.
You must also have either prediabetes combined with elevated triglycerides and low HDL cholesterol, or at least two documented clinical manifestations of obesity-caused organ dysfunction such as obstructive sleep apnea, coronary artery disease, chronic severe joint pain, or significant mobility limitations.
Six months of documented dietary changes and increased physical activity are required before initiation.
Members with a type 2 diabetes diagnosis are excluded from Zepbound coverage under this policy and would be directed to Mounjaro, which uses the same active ingredient but is approved for diabetes.

Under Enhanced, Zepbound is the plan-preferred anti-obesity agent, so Wegovy and Saxenda are only approved after you show intolerance or contraindication to Zepbound.⁷

Staying Covered After the First Approval

Approval is not the end of the review. Highmark reauthorizes Zepbound in stages, and you can lose coverage if the drug is not producing results.¹

At the continuation stage (7 to 12 months), you must have lost at least 5% of your baseline body weight, with the prescriber documenting baseline and current height, weight, and BMI.
At the maintenance stage (12 months and beyond), you must have maintained at least 5% weight loss from baseline, and the prescriber must attest to ongoing lifestyle modification.
Continuation and maintenance require a weekly dose of 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg. The 2.5 mg starter dose is initiation-only. If you have not yet reached 5 mg, the prescriber must attest you are actively titrating up.

Zepbound for Obstructive Sleep Apnea

Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, and Highmark covers this indication through a separate prior authorization pathway with its own documentation.⁸

The prescriber must be or consult with a sleep specialist and submit baseline Apnea-Hypopnea Index and Respiratory Disturbance Index scores from a polysomnography performed without positive airway pressure or oral appliances. The record must show whether you are compliant with positive airway pressure therapy (use on 70% of nights for at least four hours per night over at least two months), whether you have failed or cannot tolerate that therapy, and whether sleep hygiene modifications have been practiced for at least six months before starting Zepbound.⁸ If you also have type 2 diabetes, Highmark requires evidence that you first tried and failed a GLP-1 receptor agonist approved for diabetes before Zepbound will be authorized for the sleep apnea use.⁹

What You Will Pay

Even with coverage, your out-of-pocket cost depends on plan design, formulary tier, and whether you have met your deductible. Highmark does not publish a single price, because cost-sharing is set by the specific employer or marketplace plan.

As one concrete illustration, Penn State’s Highmark-administered plans show an allowed cost of roughly $1,036 for a one-month supply. The Lion Traditional plan charges 50% coinsurance at retail (about $518 before any manufacturer discount). The Lion Advantage HSA plan charges 20% coinsurance (about $207), but only after the deductible; before the deductible is met, you pay the full allowed cost.¹⁰

Starting in January 2025, Highmark removed weight-loss medications from its Preventive Drug List across its entire book of business, which changed how these drugs interact with deductibles and cost-sharing on many plans. If your employer still offers weight-loss drug coverage, expect higher costs than in prior years.¹¹

Manufacturer Savings Card

Eli Lilly offers a Zepbound savings card that can lower copay or coinsurance for commercially insured patients, in some cases to as little as $25 for a one- to three-month supply of the single-dose pen.¹¹ It applies as a secondary payer after insurance processes the claim.

The card cannot be used if you are enrolled in Medicare, Medicaid, TRICARE, or any other government-funded program.¹² It cannot be combined with other discount programs, and some pharmacies will not accept it. Terms and amounts can change, so check them each time you fill.

If Highmark Denies Your Prior Authorization

Denials are common with anti-obesity medications. You generally have 180 days to file an internal appeal. The denial letter will cite a specific reason, often “not medically necessary,” failure to meet BMI criteria, or formulary exclusion, and your appeal should answer that reason directly.¹³

Ask your prescriber for a detailed letter of medical necessity that references your clinical history and the trial evidence for Zepbound.
Have the prescriber request a peer-to-peer review, a direct phone call with the insurer’s medical director.
Submit recent BMI measurements (within the last 30 to 90 days), comorbidity records, and documentation of participation in a lifestyle modification program.
If the internal appeal is denied, request an independent external review at no cost. The external reviewer’s decision is binding on the insurer.¹³

In New York, Highmark’s step therapy override policy allows an exception if the preferred medication is contraindicated, expected to be ineffective based on your clinical history, has already been tried and discontinued, or would create a significant barrier to adherence or worsen a comorbid condition.¹⁴

1
Highmark. Pharmacy Policy Bulletin J-0184
2
Highmark. Medical and Drug Formulary
3
Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
4
Medicare.gov. Weight Loss Drugs
5
Highmark Health Options. Weight Loss Drugs
6
Highmark. Pharmacy Policy Bulletin J-1389
7
Highmark. Pharmacy Policy Bulletin J-1388
8
Highmark. Zepbound Prior Authorization Form
9
Highmark. Drug Formulary Update January 2025
10
Penn State Human Resources. Prescription Coverage
11
Penn State Human Resources. Weight Loss Medication Formulary Changes
12
Eli Lilly. Coverage and Savings
13
Find Honest Care. Zepbound Denied
14
Highmark. New York Step Therapy Override Exception Policy